Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 38-44

  Smee, Donald F ^a   Hurst, Brett L ^a   Wong, Min Hui ^a   Tarbet, E Bart ^a   Babu, Y S ^b   Klumpp, Klaus ^c   Morrey, John D ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

^c Roche   (United States)

Author keywords

Antiviral; Drug combination; Oseltamivir carboxylate; Peramivir; Synergy

Indexed keywords

OSELTAMIVIR; PERAMIVIR; PLACEBO; SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYCLOPENTANES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 77956937502     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.07.003     Document Type: Article

References (33)

1. Bantia S., Arnold C.S., Parker C.D., Upshaw R., Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006, 69:39-45.
2. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellog D.L., Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 2001, 45:1162-1167.
3. Barroso L., Treanor J., Gubareva L., Hayden F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir. Ther. 2005, 10:901-910.
4. Besselaar T.G., Naidoo D., Buys A., Gregory V., McAnerney J., Manamela J.M., Blumberg L., Schoub B.D. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 2008, 14:1809-1810.
5. Boltz D.A., Ilyushina N.A., Arnold C.S., Babu Y.S., Webster R.G., Govorkova E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008, 80:150-157.
6. Centers for Disease Control and Prevention (CDC) Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58:467-470.
7. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., Yuen K.Y., Webster R.G., Peiris J.S., Guan Y., Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193:1626-1629.
8. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301:1034-1041. Oseltamivir-Resistance Working Group.
9. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
10. Galabov A.S., Simeonova L., Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type 1 (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 2006, 17:251-258.
11. Gubareva L.V., Webster R.G., Hayden F.G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 2001, 45:3403-3408.
12. Hata M., Tsuzuki M., Goto Y., Kumagai N., Harada M., Hashimoto M., Tanaka S., Sakae K., Kimura T., Minagawa H., Miyazaki Y. High frequency of amantadine-resistant influenza A (H3N2) viruses in the 2005-2006 season and rapid detection of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR. Jpn. J. Infect. Dis. 2007, 60:202-204.
13. Hurt A.C., Iannello P., Jachno K., Komadina N., Hampson A.W., Barr I.G., McKimm-Breschkin J.L. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 2006, 50:1872-1874.
14. Ilyushina N.A., Bovin N.V., Webster R.G., Govorkova E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006, 70:121-131.
15. Ilyushina N.A., Hoffmann E., Salomon R., Webster R.G., Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Ther. 2007, 12:363-370.
16. Ilyushina N.A., Hay A., Yilmaz N., Boon A.C., Webster R.G., Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52:3889-3897.
17. Li W., Escarpe P.A., Eisenberg E.J., Cundy K.C., Sweet C., Jakeman K.J., Merson J., Lew W., Williams M., Zhang L., Kim C.U., Bischofberger N., Chen M.S., Mendel D.B. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 1998, 42:647-653.
18. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560. European Influenza Surveillance Scheme.
19. Memoli M.J., Hrabal R.J., Hassantoufighi A., Eichelberger M.C., Taubenberger J.K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis. 2010, 50:1252-1255.
20. Mishin V.P., Hayden F.G., Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 2005, 49:4515-4520.
21. Mossad S.B. The resurgence of swine-origin influenza A (H1N1). Cleve. Clin. J. Med. 2009, 76:337-343.
22. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., Blair P.J., de Jong M.D., Prichard M.N., Went G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.
23. Nguyen J.T., Hoopes J.D., Smee D.F., Prichard M.N., Driebe E.M., Engelthaler D.M., Le M.H., Keim P.S., Spence R.P., Went G.T. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 2009, 53:4115-4126.
24. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., Xu X., Shaw M.W., Klimov A.I., Gubareva L.V. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 2010, 85:381-388.
25. Prichard M.N., Shipman C. A three dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14:181-206.
26. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-498.
27. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., Babu Y.S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob. Agents Chemother. 2001, 45:749-757.
28. Smee D.F., Huffman J.H., Morrison A.C., Barnard D.L., Sidwell R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 2001, 45:743-748.
29. Smee D.F., Bailey K.W., Morrison A.C., Sidwell R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48:88-93.
30. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Morrey J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 2009, 53:2120-2128.
31. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Tarbet E.B., Morrey J.D., Furuta Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 2010, 54:126-133.
32. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., Ratnamohan M., McPhie K., Cunningham A.L., Saksena N.K. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res. 2010, 87:16-21.
33. Yun N.E., Linde N.S., Zacks M.A., Barr I.G., Hurt A.C., Smith J.N., Dziuba N., Holbrook M.R., Zhang L., Kilpatrick J.M., Arnold C.S., Paessler S. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008, 374:198-209.